Stay updated on FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial

Sign up to get notified when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.3 to v3.5.0. No visible changes to the Study Details page content or layout.
    Difference
    0.1%
    Check dated 2026-03-18T18:14:12.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3, indicating a recent page update. No substantive study details or user-facing content were changed.
    Difference
    0.1%
    Check dated 2026-03-11T17:49:20.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    45 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the funding-status notice and Revision: v3.4.1. These are administrative updates to the site and do not alter study details or eligibility information.
    Difference
    0.4%
    Check dated 2026-02-11T02:51:58.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    A new site-wide notice about a lapse in government funding appears on the page, and the revision tag shows v3.4.1 replacing the prior v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T00:48:43.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Added a 'Show glossary' option and updated metadata labels (including 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act data'); revision updated to v3.4.0.
    Difference
    0.2%
    Check dated 2026-01-27T22:41:43.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    Footer revision updated from v3.3.3 to v3.3.4; no modifications to core study content, eligibility criteria, contact information, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:33:18.000Z thumbnail image

Stay in the know with updates to FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.